| Sep 24 |
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
|
| Sep 24 |
Zacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGen
|
| Sep 23 |
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
|
| Sep 20 |
Longboard Stock Soars on FDA Designations for Epilepsy Drug
|
| Sep 19 |
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
|
| Sep 19 |
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
|
| Sep 17 |
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
|
| Sep 10 |
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
|
| Sep 10 |
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
|
| Sep 5 |
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
|
